Miller T P, Jones S E, Alberts D S, Mackel C
Invest New Drugs. 1984;2(1):75-7. doi: 10.1007/BF00173790.
Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without signs of phlebitis, was the most common side effect occurring in 40% of treated patients. At the doses employed bisantrene had little activity as a single agent in this group of previously treated patients with unfavorable histology NHL.
16例接受过大量预处理的晚期中、高度弥漫性非霍奇金淋巴瘤（NHL）患者，每三周接受260mg/M2的比生群治疗。共进行了30次比生群输注，但未观察到客观缓解迹象。输注侧手臂疼痛，无论有无静脉炎体征，是最常见的副作用，40%的治疗患者出现该症状。在所采用的剂量下，比生群作为单一药物，对这组先前接受过治疗且组织学不良的NHL患者几乎没有活性。
